The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program.
Iris J M LevinkSanne C JaarsmaBrechtje D M KoopmannPriscilla A van RietKasper Alexander OverbeekJihane MezianiMarloes L J A SprijRiccardo CasadeiCarlo IngaldiMarcin PolkowskiMegan M L EngelsLaurens A van der WaaijSilvia CarraraElizabeth PandoMarlies VornhülzPieter HonkoopErik J SchoonJohanna LaukkarinenJilling F BergmannGemma RossiFrederike G I van VilsterenAnne-Marie van BerkelTrevor TaboneMatthijs P SchwartzAdriaan C I T L TanJeanin E van HooftRutger QuispelEllert van SoestLaszlo CzackoMarco J BrunoDjuna L Cahennull nullPublished in: United European gastroenterology journal (2023)
In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.